Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/ADMA Biologics faces class action over alleged misleading revenue claims causing stock drop.
ADMA
$8.62
-$0.25 -2.87%

ADMA Biologics faces class action over alleged misleading revenue claims causing stock drop.

Market News
01 Jun 2026
Newsfile Corp
View Source
Bearish
pluang ai news

Rosen Law Firm is investigating a potential class action lawsuit against ADMA Biologics after allegations surfaced that the company issued misleading business information, specifically accused of channel stuffing to inflate revenue. This led to a 16.6% drop in ADMA Biologics' stock on March 24, 2026. Investors who purchased ADMA securities may be eligible for compensation through a contingency fee arrangement. The law firm is actively seeking shareholders to join the class action to recover losses caused by the alleged misconduct.

More News (ADMA)

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege the companies made f...

Market News
Bearish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App